Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung
Status:
Completed
Trial end date:
2020-01-13
Target enrollment:
Participant gender:
Summary
The main objective is to assess the efficacy of afatinib in combination with pembrolizumab,
as measured by objective response (OR) in patients with locally advanced or metastatic
squamous NSCLC who progressed during or after first line platinum-based treatment.
The secondary objectives are to confirm the RP2D, assess the safety profile, and the
secondary measures of clinical efficacy including disease control (DC), duration of objective
response (DoR), progression-free survival (PFS), overall survival (OS), and tumour shrinkage.